Clinical implications of macrolide resistance in community-acquired respiratory tract infections

Expert Review of Anti-Infective Therapy

Volumn 4, Issue 6, 2006, Pages 973-980

  Hoban, Daryl J ^a   Zhanel, George G ^a  

^a HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Azithromycin; Bacterial; Clarithromycin; Infection; Macrolide; Respiratory

Indexed keywords

14 HYDROXYCLARITHROMYCIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CLARITHROMYCIN; CLINDAMYCIN; DRUG METABOLITE; ERYTHROMYCIN; KETOLIDE; LINCOSAMIDE; MACROLIDE; MIKAMYCIN B; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TELITHROMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIINFLAMMATORY ACTIVITY; COMMUNITY ACQUIRED RESPIRATORY TRACT INFECTION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENCY; DRUG TREATMENT FAILURE; GASTROINTESTINAL SYMPTOM; HUMAN; IN VITRO STUDY; MONOTHERAPY; NONHUMAN; RESPIRATORY TRACT INFECTION; REVIEW; RISK FACTOR; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CLARITHROMYCIN; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; KETOLIDES; MACROLIDES; MICROBIAL SENSITIVITY TESTS; RESPIRATORY TRACT INFECTIONS; RISK FACTORS; STREPTOCOCCUS PNEUMONIAE;

EID: 33846025424     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.4.6.973     Document Type: Review

References (50)

1. Volturo GA, Low DE, Aghababian R. Managing acute lower respiratory tract infections in an era of antibacterial resistance. Am. J. Emergency Med. 24 (3), 329-342 (2006).
2. Woodwell DA, Cherry DK. National Ambulatory Medical Care Survey: 2002 Summary. no. 346. Hyattsville, Md: National Center for Health Statistics. Advance Data from Vital and Health Statistics. August 26 (2004).
3. Gotfried MH. Macrolides for the treatment of chronic sinusitis, asthma, and COPD. Chest 125(Suppl. 2), S52-S60 (2004).
4. Tellier G, Chang JR, Asche CV, Lavin B, Stewart J, Sullivan SD. Comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days. Curr. Med. Res. Opin. 20(5), 739-747 (2004). Erratum in: Curr. Med. Res. Opin. 20(8), 1331 (2004).
5. Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. The cost of treating community-acquired pneumonia. Clin. Ther. 20(4), 820-837 (1998).
6. File Jr. TM, Garau J, Blasi F et al. Guidelines in empiric antimicrobial prescribing in community-acquired pneumonia. Chest 125(5), 1888-1901 (2004).
7. Gotfried MH. Comparison of bacteriological eradication of Streptococcus pneumoniae by clarithromycin and reports of increased antimicrobial resistance. Clin. Ther. 22(1), 2-14 (2000).
8. Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. Treatment cost of acute exacerbations of chronic bronchitis. Clin. Ther. 21(3), 576-591 (1999).
9. Anzueto A, Norris S. Clarithromycin in 2003; sustained efficacy and safety in the era of rising antibiotic resistance. Int. J. Antimicrob. Agents 24(1), 1-17 (2004).
10. McCarty JM. Clarithromycin in the management of community-acquired pneumonia. Clin. Ther. 22(3), 281-294, Discussion 265 (2000).
11. Nuermberger E, Bishai WR. The clinical significance of macrolide-resistant Streptococcus pneumoniae: it's all relative. Clin. Infect. Dis. 38(1), 99-103 (2004).
12. Wierzbowski AK, Hoban DJ, Hisanaga T, DeCorby M, Zhanel G. The use of macrolides in treatment of upper respiratory tract infections. Curr. Infect. Dis. Rep. 7(3), 175-184 (2005).
13. Mandell LA, Bartlett JG, Dowell SF, File TM, Musher DM, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin. Infect. Dis. 37(11), 1405-1433 (2003).
14. Roberts MC, Sutcliffe J, Courvalin P, Jensen LB, Rood J, Seppala H. Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants. Antimicrob. Agents Chemother. 43(12), 2823-2830 (1999).
15. Amsden GW. Advanced-generation macrolides: tissue-directed antibiotics. Int. J. Antimicrob. Agents. 18(Suppl. 1), S11-S15 (2001).
16. Jain R, Danziger LH. The macrolide antibiotics: a pharmacokinetic and pharmacodynamic overview. Curr. Pharm. Des. 10(25), 3045-3053 (2004).
17. Zuckerman JM. The newer macrolides: azithromycin and clarithromycin. Infect. Dis. Clin. North Am. 14(2), 449-462 (2000).
18. Doern GV. Antimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumoniae in the United States. Clin. Infect. Dis. 33(Suppl. 3), S187-S192 (2001).
19. Zhanel GG. Antibacterial drivers of resistance. Treat. Respir. Med. 4(Suppl. 1), S13-S18 (2005).
20. Doern GV, Richter SS, Miller A et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antibiotic classes? Clin. Infect. Dis. 41, 139-148 (2005).
21. Patel KB, Xuan D, Tessier PR, Russomanno JH, Quintiliani R, Nightingale CH. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob. Agents Chemother. 40(10), 2375-2379(1996).
22. Gotfried MH, Danziger LH, Rodvold KA. Steady-state plasma and bronchopulmonary characteristics of clarithromycin extended-release tablets in normal healthy adult subjects. J. Antimicrob. Chemother. 52(3), 450-456 (2003).
23. Conte Jr. JE, Golden JA, Duncan S, McKenna E, Zurlinden E. Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin. Antimicrob. Agents. Chemother. 39(2), 33-48 (1995).
24. Rodvold KA, Gotfried MH, Danziger LH, Servi RJ. Intrapulmonary steady-state of clarithromycin and azithromycin in healthy adult volunteers. Antimicrob. Agents Chemother. 41(6), 1399-1402 (1997).
25. Jorgensen JH, Maher LA, Howell AW. Activity of clarithromycin and its principal human metabolite against Haemophilus influenzae. Antimicrob. Agents Chemother. 35(7), 1524-1526 (1991).
26. Kostadima E, Tsiodras S, Alexopoulos EI et al. Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma. Eur. Respir. J. 23(5), 714-717 (2004).
27. Bishai WR. Clinical significance of pneumococcal resistance and factors influencing outcomes. Treat. Resp. Med. 4(Suppl. 1), 19-23 (2005).
28. Rechtweg JS, Moinuddin R, Houser SM, Mamikoglu B, Corey JP. Quality of life in treatment of acute rhinosinusitis with clarithromycin and amoxicillin/clavulanate. Laryngoscope 114(5), 806-810 (2004).
29. Tellier G, Niederman MS, Nusrat R, Patel M, Lavin B. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J. Antimicrob. Chemother. 54(2), 515-523 (2004).
30. Khair OA, Andrews JM, Honeybourne D, Jevons G, Vacheron F, Wise R. Lung concentrations of telithromycin after oral dosing. J. Antimicrob. Chemother. 47(6), 837-840 (2001).
31. Reinert RR, van der Linden M, Al-Lahham A. Molecular characterization of the first telithromycin-resistant Streptococcus pneumoniae isolate in Germany. Antimicrob. Agents Chemother. 49(8), 3520-3522 (2005).
32. Rantala M, Haanpera-Heikkinen M, Lindgren M, Seppala M, Houvinen P, Jalava J. Streptococcus pneumoniae isolates resistant to telithromycin. Antimicrob. Agents Chemother. 50(5), 1855-1888 (2006).
33. Lonks JR, Garau J, Gomez L et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin. Infect. Dis. 35(5), 556-564 (2003).
34. Jacobs MR. In vivo veritas: in v;tro macrolide resistance in systemic Streptococcus pneumoniae infections does result in clinical failure. Clin. Infect. Dis. 35(5), 56-59 (2002).
35. Rzeszutek M,. Wierzbowski A, Hoban DJ, Conly J, Bishai W, Zhanel GG. A review of clinical failures associated with macrolide-resistant Streptococcus pneumoniae. Int. J. Antimicrob. Agents. 24(2), 95-104 (2004).
36. Daneman N, McGeer A, Green K, Low DE. Macrolide resistance in bacteremic pneumococcal disease: Implications for patient management. Clin. Infect. Dis. 43(4), 432-438 (2006).
37. Hoban D, Waites K, Felmingham D. Antimicrobial susceptibility of community acquired respiratory tract pathogens in North America in 1999-2000: findings of the PROTEKT surveillance study. Diagn. Microbiol Infect. Dis. 45(4), 251-259 (2003).
38. Doern GV, Brown SD. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-2001. J. Int Infect. 48(1), 56-65 (2004).
39. Thornsberry C, Sahm DF, Kelly LJ et al. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST surveillance program, 1999-2000. Clin. Infect. Dis. 34(Suppl. 1), S4-S16 (2002).
40. Jacobs MR, Felmingham D, Appelbaum PC, Grüneberg RN, The Alexander Project Group. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J. Antimicrob. Chemother. 52(2), 229-246 (2003).
41. Washington JA, The Alexander Project Group. A multi-center study of the antimicrobial susceptibility of community-acquired lower respiratory tract pathogens in the United States, 1992-1994. The Alexander project. Diagn. Microbiol. Infect. Dis. 25(4), 183-190 (1996).
42. Doern GV, Heilmann KP, Huynh HK, Rhomberg PR, Coffman SL, Brueggemann AB. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 19992000, including a comparison of resistance rates since 1994-1995. Antimicrob. Agents. Chemother. 45(6), 1721-1729 (2001).
43. Lynch JP, Martinez FJ. Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia. Clin. Infect. Dis. 34(Suppl. 1), S27-S46 (2002).
44. Bishai W. The in-vivo in vitro paradox in pneumococcal respiratory tract infections. J. Antimicrob. Chemother. 49(3), 433-436 (2002).
45. File TM. Solution to the problem of bacterial resistance. Treat Respir. Med. 4(Suppl 1), 25-30 (2005).
46. Zhanel GG, DeCorby M, Noreddin A et al. Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations. J. Antimicrob. Chemother. 52(1), 83-88 (2003).
47. Ambrose PG. Antimicrobial susceptibility breakpoints. PK-PD and susceptibility breakpoints. Treat. Resp. Med. 4(Suppl. 1), S5-S11 (2005).
48. Lonks JR, Goldman DA. Telithromycin: a ketolide antibiotic for treatment of respiratory tract infections. Clin. Infect. Dis. 40(11), 1657-1664 (2005).
49. Al-Tatari H, Abdel-Haq N, Chearskull P, Asmar B. Antibiotics for treatment of resistant Gram-positive coccal infections. Indian J. Pediatr 73(4), 323-334 (2006).
50. Hoban H, Felmingham D. The PROTEKT surveillance study: antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections. J. Antimicrob. Chemother. 50(Suppl. S1), S49-S59 (2002).